NCT00464178 2022-07-20
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
Clinical Trials
6 trialsNCT00985907 2020-06-17
DMV
University of California, San Francisco
Phase 1/2 Terminated
NCT01438177 2020-02-24
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
Phase 2 Terminated
NCT01315873 2018-02-07
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
Phase 2 Terminated
NCT00744354 2018-01-18
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00983346 2016-07-11
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
Phase 2 Terminated